Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 33346662)

  • 1. Altered Gut Microbiome under Antiretroviral Therapy: Impact of Efavirenz and Zidovudine.
    Ray S; Narayanan A; Giske CG; Neogi U; Sönnerborg A; Nowak P
    ACS Infect Dis; 2021 May; 7(5):1104-1115. PubMed ID: 33346662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gut microbiota alterations after switching from a protease inhibitor or efavirenz to raltegravir in a randomized, controlled study.
    Hanttu AM; Pekkala S; Satokari R; Hartikainen AK; Arkkila P; Pietiläinen KH; Sutinen JP
    AIDS; 2023 Feb; 37(2):323-332. PubMed ID: 36541643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of long-term antiretroviral therapy on gut and oral microbiotas in HIV-1-infected patients.
    Imahashi M; Ode H; Kobayashi A; Nemoto M; Matsuda M; Hashiba C; Hamano A; Nakata Y; Mori M; Seko K; Nakahata M; Kogure A; Tanaka Y; Sugiura W; Yokomaku Y; Iwatani Y
    Sci Rep; 2021 Jan; 11(1):960. PubMed ID: 33441754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naïve subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934.
    Margot NA; Enejosa J; Cheng AK; Miller MD; McColl DJ;
    J Acquir Immune Defic Syndr; 2009 Oct; 52(2):209-21. PubMed ID: 19644384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.
    Dahourou DL; Amorissani-Folquet M; Malateste K; Amani-Bosse C; Coulibaly M; Seguin-Devaux C; Toni T; Ouédraogo R; Blanche S; Yonaba C; Eboua F; Lepage P; Avit D; Ouédraogo S; Van de Perre P; N'Gbeche S; Kalmogho A; Salamon R; Meda N; Timité-Konan M; Leroy V;
    BMC Med; 2017 Apr; 15(1):85. PubMed ID: 28434406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
    Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
    Cochrane Database Syst Rev; 2013 Jun; (6):CD008270. PubMed ID: 23740608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effects of antiretrovirals on microbial translocation and gut microbiota composition of HIV-infected patients.
    Villanueva-Millán MJ; Pérez-Matute P; Recio-Fernández E; Lezana Rosales JM; Oteo JA
    J Int AIDS Soc; 2017 Mar; 20(1):21526. PubMed ID: 28362071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin-Like Growth Factor Is Associated with Changes in Body Composition with Antiretroviral Therapy Initiation.
    Erlandson KM; Fiorillo SP; Cardoso SW; Riviere C; Sanchez J; Hakim J; Kumarasamy N; Badal-Faesen S; Lalloo U; Kumwenda J; Campbell TB; Brown TT
    AIDS Res Hum Retroviruses; 2017 Sep; 33(9):929-934. PubMed ID: 28403619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Mbuagbaw LC; Irlam JH; Spaulding A; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2010 Dec; (12):CD004246. PubMed ID: 21154355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Highly Active Antiretroviral Therapy on Albuminuria in HIVinfected Persons.
    Adedeji TA; Adebisi SA; Adedeji NO
    Infect Disord Drug Targets; 2020; 20(3):374-384. PubMed ID: 31389318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Spaulding A; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2010 Oct; (10):CD008740. PubMed ID: 20927777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral and Gut Microbial Diversity and Immune Regulation in Patients with HIV on Antiretroviral Therapy.
    Annavajhala MK; Khan SD; Sullivan SB; Shah J; Pass L; Kister K; Kunen H; Chiang V; Monnot GC; Ricupero CL; Mazur RA; Gordon P; de Jong A; Wadhwa S; Yin MT; Demmer RT; Uhlemann AC
    mSphere; 2020 Feb; 5(1):. PubMed ID: 32024712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gut microbiota diversity predicts immune status in HIV-1 infection.
    Nowak P; Troseid M; Avershina E; Barqasho B; Neogi U; Holm K; Hov JR; Noyan K; Vesterbacka J; Svärd J; Rudi K; Sönnerborg A
    AIDS; 2015 Nov; 29(18):2409-18. PubMed ID: 26355675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different Degrees of Immune Recovery Using Antiretroviral Regimens with Vonavir or Zidovudine/Lamivudine/Efavirenz in HIVPositive Patients Receiving First Line Treatment in Iran.
    Sadeghi L; Moallemi S; Tabatabai RA; Esmaeilzadeh A; Ahsani-Nasab S; Ahmadi NE; Bayanolhagh S; Lolaie M; Narouei A; SeyedAlinaghi S; Mohraz M
    Infect Disord Drug Targets; 2018; 18(3):207-213. PubMed ID: 29308748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fecal Bacterial Communities in treated HIV infected individuals on two antiretroviral regimens.
    Pinto-Cardoso S; Lozupone C; Briceño O; Alva-Hernández S; Téllez N; Adriana A; Murakami-Ogasawara A; Reyes-Terán G
    Sci Rep; 2017 Mar; 7():43741. PubMed ID: 28262770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alterations in the gut microbiota of patients with acquired immune deficiency syndrome.
    Zhou Y; Ou Z; Tang X; Zhou Y; Xu H; Wang X; Li K; He J; Du Y; Wang H; Chen Y; Nie Y
    J Cell Mol Med; 2018 Apr; 22(4):2263-2271. PubMed ID: 29411528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of drug resistance mutations in HAART patients infected with HIV-1 CRF06_cpx in Estonia.
    Avi R; Pauskar M; Karki T; Kallas E; Jõgeda EL; Margus T; Huik K; Lutsar I
    J Med Virol; 2016 Mar; 88(3):448-54. PubMed ID: 26291050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the intestinal microbiota in MSM with HIV infection.
    Fu Y; Ke S; Tang G; Guo Q; Guo Q; Wang Z; Leng R; Fan Y
    BMC Microbiol; 2024 Jun; 24(1):192. PubMed ID: 38831399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized controlled trial of single-class maintenance therapy with abacavir/lamivudine/zidovudine after standard triple antiretroviral induction therapy: final 96-week results from the FREE study.
    Sprenger HG; Langebeek N; Mulder PG; Ten Napel CH; Vriesendorp R; Hoepelman AI; Legrand JC; Koopmans PP; Bravenboer B; Ten Kate RW; Groeneveld P; Bierman W; van der Werf Ts; Gisolf E; Richter C
    HIV Med; 2015 Feb; 16(2):122-31. PubMed ID: 25472825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patients.
    Markowitz M; Hill-Zabala C; Lang J; DeJesus E; Liao Q; Lanier ER; Davis EA; Shaefer M;
    J Acquir Immune Defic Syndr; 2005 Jul; 39(3):257-64. PubMed ID: 15980684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.